Clear all

Refine your search

Content type
Tags
Firm name
Author
Jurisdiction
Language

531 results found

Article
Ask Lexy

Shearman & Sterling LLP | USA | 9 Apr 2019

Southern District Of New York Pares Claims In Putative Class Action Against Pharmaceutical Company

On March 29, 2019, Judge J. Paul Oetken of the United States District Court for the Southern District of New York partially granted a motion to…
Article
Ask Lexy

Knobbe Martens | USA | 9 Apr 2019

Federal Circuit Review - March 2019

In Mylan Pharmaceuticals Inc. v. Research Corporation Tech., Appeal Nos. 2017-2088, -2089, -2091, the Federal Circuit held that a party joined to an…
Article
Ask Lexy

Jones Day | USA | 5 Apr 2019

Seeing Multiple: Observations from Petitioner Filing Strategies Following SAS

In April 2018, the United States Supreme Court held that the PTAB must issue a final written decision addressing every patent claim challenged in an…
Article
Ask Lexy

McDermott Will & Emery | USA | 28 Mar 2019

Representation of opposing party’s corporate subsidiary can cause disqualification

The US Court of Appeals for the Federal Circuit concluded that a firm's ongoing representation of the opposing parties' indirect subsidiary and…
Article
Ask Lexy

McDermott Will & Emery | USA | 28 Mar 2019

Mootness on appeal from PTAB

The US Court of Appeals for the Federal Circuit dismissed an appeal of an inter partes review (IPR), finding that the challenger lacked appellate…
Article
Ask Lexy

K&L Gates LLP | USA | 21 Mar 2019

The Federal Circuit Dismisses Biosimilar Petitioner’s IPR Appeal for Lack of Standing Due to Mootness

In Momenta Pharmaceuticals, Inc. v. Bristol-Myers Squibb Company, the Federal Circuit dismissed a biosimilar petitioner's appeal of an adverse inter…
Article
Ask Lexy

Miller Canfield PLC | USA | 20 Mar 2019

Patent Trial and Appeal Board Gives Green Light to Same-Party and Issue Joinder

The Patent Trial and Appeal Board ("PTAB") has issued a precedential opinion that gives a green light to same-party and issue joinder. This practice…
Article
Ask Lexy

Dilworth IP | USA | 19 Mar 2019

Lead Compound Analysis in Mylan v. RCT

Lead compound analysis (LCA) has been used in the evaluation of chemical compound Obviousness for the past 20 years.[1] This approach supplemented the…
Article
Ask Lexy

McDermott Will & Emery | USA | 26 Feb 2019

If it ain’t broke: motivation to modify compound must consider all its characteristics

Affirming a Patent Trial and Appeal Board (PTAB) decision finding claims directed to an epilepsy drug patentable, the US Court of Appeals for the…
Article
Ask Lexy

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP | USA | 15 Feb 2019

No Standing On Appeal From Board Decision After Abandoning Product Development

In Momenta Pharmaceuticals, Inc. v. Bristol-Meyers Squibb Co., No. 17-1694 (Fed. Cir. Feb. 7, 2019), the Federal Circuit dismissed for lack of…
Previous page 1 2 3 ...